106 related articles for article (PubMed ID: 22682594)
1. [Postmarketing surveillance study on the use of topotecan in small-cell lung cancer. Use of topotecan in a pneumology university department].
Hureaux J; Alizon C; Urban T
Rev Mal Respir; 2012 May; 29(5):680-7. PubMed ID: 22682594
[TBL] [Abstract][Full Text] [Related]
2. [Effect of topotecan as a second line treatment in small cell lung cancer patients. Preliminary report].
Biernacka B; Krawczyk P; Buczkowski J; Siwiec A; Perzyło K; Milanowski J
Pneumonol Alergol Pol; 2010; 78(3):192-202. PubMed ID: 20461687
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy.
Jotte R; Conkling P; Reynolds C; Galsky MD; Klein L; Fitzgibbons JF; McNally R; Renschler MF; Oliver JW
J Clin Oncol; 2011 Jan; 29(3):287-93. PubMed ID: 21135284
[TBL] [Abstract][Full Text] [Related]
4. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.
Ardizzoni A; Manegold C; Debruyne C; Gaafar R; Buchholz E; Smit EF; Lianes P; ten Velde G; Bosquee L; Legrand C; Neumaier C; King K;
Clin Cancer Res; 2003 Jan; 9(1):143-50. PubMed ID: 12538462
[TBL] [Abstract][Full Text] [Related]
5. Topotecan in the treatment of elderly patients with relapsed small-cell lung cancer.
Garst J; Buller R; Lane S; Crawford J
Clin Lung Cancer; 2005 Nov; 7(3):190-6. PubMed ID: 16354314
[TBL] [Abstract][Full Text] [Related]
6. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.
Eckardt JR; von Pawel J; Pujol JL; Papai Z; Quoix E; Ardizzoni A; Poulin R; Preston AJ; Dane G; Ross G
J Clin Oncol; 2007 May; 25(15):2086-92. PubMed ID: 17513814
[TBL] [Abstract][Full Text] [Related]
7. Effect of topotecan as second-line chemotherapy for small cell lung cancer patients with interstitial lung disease.
Suzuki H; Hirashima T; Kobayashi M; Sasada S; Okamoto N; Uehara N; Matsuura Y; Tamiya M; Morishita N; Higashiguchi M; Tsumori T; Kawase I
J Chemother; 2011 Dec; 23(6):367-70. PubMed ID: 22233823
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers.
Schaefer PL; Marks RS; Mahoney MR; Sloan JA; Bauman MD; Tazelaar HD; Kugler JW; Mailliard JA; Ebbert LP; Wiesenfeld M
Am J Clin Oncol; 2003 Jun; 26(3):236-40. PubMed ID: 12796591
[TBL] [Abstract][Full Text] [Related]
9. Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy.
Evans TL; Cho BC; Udud K; Fischer JR; Shepherd FA; Martinez P; Ramlau R; Syrigos KN; Shen L; Chadjaa M; Wolf M
J Thorac Oncol; 2015 Aug; 10(8):1221-8. PubMed ID: 26200278
[TBL] [Abstract][Full Text] [Related]
10. Topotecan-carboplatin-etoposide combination as 1st line treatment in patients with small cell lung cancer.
Zarogoulidis K; Mylonaki E; Kakavelas P; Zarogoulidis P; Tsiouda T; Rapti E; Lithoxopoulou H; Zarogoulidou V; Kontakiotis T;
Lung Cancer; 2009 Nov; 66(2):226-30. PubMed ID: 19321222
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.
Inoue A; Sugawara S; Yamazaki K; Maemondo M; Suzuki T; Gomi K; Takanashi S; Inoue C; Inage M; Yokouchi H; Watanabe H; Tsukamoto T; Saijo Y; Ishimoto O; Hommura F; Nukiwa T
J Clin Oncol; 2008 Nov; 26(33):5401-6. PubMed ID: 18854562
[TBL] [Abstract][Full Text] [Related]
12. Topotecan in the treatment of recurrent small cell lung cancer: an update.
Ardizzoni A
Oncologist; 2004; 9 Suppl 6():4-13. PubMed ID: 15616145
[TBL] [Abstract][Full Text] [Related]
13. [Clinical study of topotecan in the treatment of small cell lung cancer and recurrent ovarian cancer].
Feng F; He X; Shi Y
Zhonghua Zhong Liu Za Zhi; 2001 Mar; 23(2):155-8. PubMed ID: 11783024
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401.
Nogami N; Hotta K; Kuyama S; Kiura K; Takigawa N; Chikamori K; Shibayama T; Kishino D; Hosokawa S; Tamaoki A; Harita S; Tabata M; Ueoka H; Shinkai T; Tanimoto M
Lung Cancer; 2011 Oct; 74(1):80-4. PubMed ID: 21334093
[TBL] [Abstract][Full Text] [Related]
15. Phase III study comparing sequential versus alternate administration of cisplatin-etoposide and topotecan as first-line treatment in small cell lung cancer.
Baka S; Agelaki S; Kotsakis A; Veslemes M; Papakotoulas P; Agelidou M; Agelidou A; Tsaroucha E; Pavlakou G; Gerogianni A; Androulakis N; Vamvakas L; Kalbakis K; Mavroudis D; Georgoulias V
Anticancer Res; 2010 Jul; 30(7):3031-8. PubMed ID: 20683051
[TBL] [Abstract][Full Text] [Related]
16. Topotecan in the treatment of brain metastases. A phase II study of GOIM (Gruppo Oncologico dell'Italia Meridionale).
Lorusso V; Galetta D; Giotta F; Rinaldi A; Romito S; Brunetti C; Silvestris N; Colucci G
Anticancer Res; 2006; 26(3B):2259-63. PubMed ID: 16821598
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancer.
Spigel DR; Greco FA; Burris HA; Shipley DL; Clark BL; Whorf RC; Arrowsmith ER; Hainsworth JD
Clin Lung Cancer; 2011 May; 12(3):187-91. PubMed ID: 21663862
[TBL] [Abstract][Full Text] [Related]
18. Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen.
Reck M; Groth G; Buchholz E; Goetz E; Gatzemeier U; Manegold C
Lung Cancer; 2005 Jun; 48(3):409-13. PubMed ID: 15893010
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of oral topotecan in advanced non-small cell lung cancer.
White SC; Cheeseman S; Thatcher N; Anderson H; Carrington B; Hearn S; Ross G; Ranson M
Clin Cancer Res; 2000 Mar; 6(3):868-73. PubMed ID: 10741709
[TBL] [Abstract][Full Text] [Related]
20. A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer.
Quoix E; Breton JL; Gervais R; Wilson J; Schramel F; Cardenal F; Ross G; Preston A; Lymboura M; Mattson K
Lung Cancer; 2005 Aug; 49(2):253-61. PubMed ID: 16022920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
